Dirk Bongard

Dirk Bongard

Auto-generated profile, based on publicly available information

Dirk Bongard

Institute of Chemistry of New Materials University of Osnabrück Barbarastr. 7 49069 Osnabrück Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JRJeany M. Rademaker-Lakhai
Jeany M. Rademaker-Lakhai
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
DPDick Pluim
Dick Pluim
JBJos H. Beijnen
Jos H. Beijnen
JSJan H. M. Schellens
Jan H. M. Schellens
Purpose: NAMI-A {H2Im[trans-RuCl4(DMSO)HIm] or imidazolium-trans-DMSO-imidazole-tetrachlororuthenate} is a novel ruthenium-containing compound that has demonstrated antimetastatic activity in preclinical studies. This Phase I study was designed to determine the maximum-tolerated dose (MTD), profile of adverse events, and dose-limiting toxicity of NAMI-A in patients with solid tumors. Furthermore, the ruthenium pharmacokinetics (PK) after NAMI-A administration and preliminary antitumor activity were evaluated. Patients and Methods: Adult patients with solid tumors received NAMI-A as an i.v. infusion over 3 h daily for 5 days every 3 weeks. PK of total and unbound ruthenium was determined during the first and second treatment using noncompartmental pharmacokinetic analysis. The total accumulation of ruthenium in WBCs was also quantified. Results: Twenty-four patients were treated at 12 dose levels (2.4–500 mg/m2/day). At 400 mg/m2/day, blisters developed on the hands, fingers, and toes. At 500 mg/m2/day, blisters persisted from weeks to months and slowly regressed. Although no formal common toxicity criteria (CTC) grade 3 developed, painful blister formation was considered dose limiting. Because the first signs developed at 400 mg/m2/day, the advised dose for further testing of NAMI-A was determined to be 300 mg/m2/day on this schedule. PK analysis revealed a linear relationship between dose and area under the concentration-time curve (AUC) of total and unbound ruthenium (R2 = 0.75 and 0.96, respectively) over the whole dose range. Plasma clearance of total ruthenium was 0.17 ± 0.09 liter/h, and terminal half-life was 50 ± 19 h. The volume of distribution at steady state of total ruthenium was 10.1 ± 2.8 liters. The accumulation of ruthenium in WBC was not directly proportional to the increasing total exposure to ruthenium. One patient with pretreated and progressive nonsmall cell lung cancer had stable disease for 21 weeks. Conclusion: NAMI-A can be administered safely as a 3-h i.v. infusion at a dose of 300 mg/m2/day for 5 days, every 3 weeks.

1 April 2020 in Radiology
Verified
Journal Article
Closed access
SVSanne G. M. van Velzen
Sanne G. M. van Velzen
NLNikolas Lessmann
Nikolas Lessmann
BVBirgitta K. Velthuis
Birgitta K. Velthuis
IBIngrid E. M. Bank
Ingrid E. M. Bank
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
IIIvana Išgum
Ivana Išgum
A deep learning calcium scoring method can accurately determine cardiovascular risk from a range of CT scan protocols. Background Although several deep learning (DL) calcium scoring methods have achieved excellent performance for specific CT protocols, their performance in a range of CT examination types is unknown...

1 April 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MJMarkus Joerger
Markus Joerger
AHAlwin D.R. Huitema
Alwin D.R. Huitema
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
JSJan H.M. Schellens
Jan H.M. Schellens
JBJos H. Beijnen
Jos H. Beijnen
Background: The aim of this study was to quantitatively assess the effect of anthropometric and biochemical variables and third-space effusions on paclitaxel pharmacokinetics in solid tumor patients. Materials and Methods: Plasma concentration-time data of paclitaxel were collected in patients with non–small cell lung cancer (n = 84), ovarian cancer (n = 40), and various solid tumors (n = 44), totaling 168 patients. Paclitaxel was given as a 3-hour infusion (n = 163) at doses ranging from 100 to 250 mg/m2, or as a 24-hour infusion (n = 5) at a dose of 135 or 175 mg/m2. Data were analyzed using nonlinear mixed-effect modeling. Results: A three-compartment model with saturable elimination and distribution was used to describe concentration-time data. Male gender and body surface area were positively correlated with maximal elimination capacity of paclitaxel (VMEL); patient age and total bilirubin were negatively correlated with VMEL (P < 0.005 for all correlations). Typically, male patients had a 20% higher VMEL; a 0.2 m2 increase of body surface area led to a 9% increase of VMEL; a 10-year increase of patient age led to a 5% decrease of VMEL; and a 10-μmol increase of total bilirubin led to a 14% decrease of VMEL. Third-space effusions were not correlated with paclitaxel pharmacokinetics. Conclusions: This extended retrospective population analysis showed patient gender to significantly and independently affect paclitaxel distribution and elimination. Body surface area, total bilirubin, and patient age were confirmed to affect paclitaxel elimination. This pharmacokinetic model allowed quantification of the covariate effects on the elimination of paclitaxel and may be used for covariate-adapted paclitaxel dosing.

27 September 2005 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MJM. Joerger
M. Joerger
AHA. D. R. Huitema
A. D. R. Huitema
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
PBP. Baas
P. Baas
JSJ. H. Schornagel
J. H. Schornagel
JBJ. H. Beijnen
J. H. Beijnen
Aims: To characterize determinants of the elimination of methotrexate (MTX) and 7‐hydroxy‐methotrexate (7‐OH‐MTX) in patients receiving high‐dose MTX therapy (HDMTX).Methods: 24 and 48‐h blood samples from 76 patients receiving HDMTX (dose range 300 mg m−2 to 12 g m−2) were analysed, and concentration‐time data were subjected to population pharmacokinetic and covariate analysis using nonlinear mixed‐effect modelling (NONMEM).Results: Treatment‐related mortality was 1.3% (one patient with renal failure). Values for MTX clearance (CLMTX) and 7‐OH‐MTX clearance (CL7‐OH‐MTX) were estimated at 8.85 and 2 L−1, respectively. Baseline creatinine clearance correlated with CLMTX and CL7‐OH‐MTX. Concurrent administration of benzimidazoles led to a 27% decrease in CLMTX and a 39% decrease in CL7‐OH‐MTX. Prior administration of nonsteroidal anti‐inflammatory drugs (NSAIDs) resulted in a 16% decrease in CLMTX and a 38% decrease in CL7‐OH‐MTX. Plasma MTX concentrations were significantly higher in patients also receiving benzimidazoles at 24 h (2.01 µmol L−1vs. 0.66 µmol L−1, P < 10−4) and at 48 h (0.25 µmol L−1vs. 0.12 µmol L−1, P < 10−4). 7‐OH‐MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 µmol L−1vs. 2.52 µmol L−1, P = 0.0009) and at 48 h (1.11 µmol L−1vs. 0.72 µmol L−1, P = 0.031).Conclusions: In patients receiving HDMTX, concurrent administration of benzimidazoles was associated with a significant decrease of CLMTX and CL7‐OH‐MTX, resulting in significantly higher plasma concentrations of MTX and 7‐OH‐MTX. The data suggest that benzimidazole treatment should be seen as a relative contraindication for HDMTX.

12 December 2012 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
LMLaura G. Merckel
Laura G. Merckel
LBLambertus W. Bartels
Lambertus W. Bartels
MKMax O. Köhler
Max O. Köhler
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
RDRoel Deckers
Roel Deckers
MBMaurice A. A. J. van Den Bosch
Maurice A. A. J. van Den Bosch

6 August 2013 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
THTristan C F van Heijst
Tristan C F van Heijst
MHMariska D Den Hartogh
Mariska D Den Hartogh
JLJan J W Lagendijk
Jan J W Lagendijk
HBH. J. G. Desiree Van Den Bongard
H. J. G. Desiree Van Den Bongard
BABram van Asselen
Bram van Asselen
The UMC Utrecht MRI/linac (MRL) design provides image guidance with high soft-tissue contrast, directly during radiotherapy (RT). Breast cancer patients are a potential group to benefit from better guidance in the MRL. However, due to the electron return effect, the skin dose can be increased in presence of a magnetic field. Since large skin areas are generally involved in breast RT, the purpose of this study is to investigate the effects on the skin dose, for whole-breast irradiation (WBI) and accelerated partial-breast irradiation (APBI). In ten patients with early-stage breast cancer, targets and organs at risk (OARs) were delineated on postoperative CT scans co-registered with MRI. The OARs included the skin, comprising the first 5 mm of ipsilateral-breast tissue, plus extensions. Three intensity-modulated RT techniques were considered (2× WBI, 1× APBI). Individual beam geometries were used for all patients. Specially developed MRL treatment-planning software was used. Acceptable plans were generated for 0 T, 0.35 T and 1.5 T, using a class solution. The skin dose was augmented in WBI in the presence of a magnetic field, which is a potential drawback, whereas in APBI the induced effects were negligible. This opens possibilities for developing MR-guided partial-breast treatments in the MRL.